Premium
Cephalon (MM) (CEPH)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Oxford BioTherapeutics Appoints Bryan G. Morton as Chairman PR Newswire OXFORD, England, June 26, 2013 OXFORD, England, June 26, 2013 /PRNewswire/ -- Oxford BioTherapeutics (OBT), a global...
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has completed its acquisition of Cephalon, Inc. (NASDAQ: CEPH). The combined company will have a...
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Cephalon Inc. (NASDAQ: CEPH) announced today that they received approval from the European Commission to proceed with...
S&P Indices Announces Change to U.S. Index PR Newswire NEW YORK, Oct. 11, 2011 NEW YORK, Oct. 11, 2011 /PRNewswire/ -- TE Connectivity Ltd. (NYSE: TEL) will replace Cephalon Inc. (NASD: CEPH) in...
Zacks Sell List Highlights: Molex, CenturyLink, Blue Nile and Cephalon PR Newswire CHICAGO, Sept. 7, 2011 CHICAGO, Sept. 7, 2011 /PRNewswire/ -- Zacks.com releases details on a group of stocks...
Cephalon Gives Notice of Anticipated Fundamental Change to Holders of Its 2.50% Convertible Senior Subordinated Notes due 2014 and 2.00% Convertible Senior Subordinated Notes due 2015 PR...
Cephalon Reported Financial Results for the Second Quarter of 2011 Sales For The Period Were $730 Million Basic Income Per Common Share Increased 31 Percent PR Newswire FRAZER, Pa., Aug. 2, 2011...
The Zacks Analyst Blog Highlights: Mylan, AstraZeneca, Novartis, Cephalon and Moody’s Corp PR Newswire CHICAGO, July 28, 2011 CHICAGO, July 28, 2011 /PRNewswire/ -- Zacks.com announces the list...
Cephalon Receives FDA Approval for Risk Evaluation and Mitigation Strategy for FENTORA and ACTIQ PR Newswire FRAZER, Pa., July 21, 2011 FRAZER, Pa., July 21, 2011 /PRNewswire/ -- Cephalon, Inc...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
